Sugi Predict

Sugi Predict / Compounds / SCHEMBL2211995

SCHEMBL2211995

SCHEMBL2211995

Cn1[nH]c2cc(=O)n(CC3CCN(C(=O)OC(C)(C)C)CC3)c(-c3ccc(Cl)cc3)c2c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CACNB4 O00305 2/20 0.42
▸ CACNA1A O00555 2/20 0.42
▸ CACNA1G O43497 2/20 0.42
▸ CACNG3 O60359 2/20 0.42
▸ CACNA1F O60840 2/20 0.42
▸ CACNA1H O95180 2/20 0.42
▸ CACNB3 P54284 2/20 0.42
▸ CACNA2D1 P54289 2/20 0.42
▸ CACNG7 P62955 2/20 0.42
▸ CACNA1B Q00975 2/20 0.42
▸ CACNA1D Q01668 2/20 0.42
▸ CACNB1 Q02641 2/20 0.42
▸ CACNG1 Q06432 2/20 0.42
▸ CACNB2 Q08289 2/20 0.42
▸ CACNA1S Q13698 2/20 0.42
▸ CACNA1C Q13936 2/20 0.42
▸ CACNA1E Q15878 2/20 0.42
▸ CACNA2D4 Q7Z3S7 2/20 0.42
▸ CACNA2D3 Q8IZS8 2/20 0.42
▸ CACNG8 Q8WXS5 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3155704 0.69 STS (0.56) STSKDM4EMEN1KMT2ANPSR1
SCHEMBL6150400 0.68 KDM4E (0.54) KDM4EMAPTTHRBKMT2APTPN2
SCHEMBL10305337 0.68 STS (0.41) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL2775887 0.68 STS (0.46) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL20015397 0.68 FAAH (0.66) STSKDM4EMEN1KMT2ANPSR1
SCHEMBL15535953 0.67 ALDH1A1 (0.52) CNR1STSKDM4EMAPTMEN1
SCHEMBL8310737 0.67 NAMPT (0.60) CNR1STSKDM4EMAPTTHRB
SCHEMBL15537093 0.67 KMT2A (0.58) CNR1STSKDM4EMEN1KMT2A
SCHEMBL3256200 0.67 GPR119 (0.57) STSKDM4EMEN1KMT2A
SCHEMBL17796243 0.67 TSHR (0.64) KDM4EMAPTMEN1KMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342203-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-11-04 — — EP claimed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 — — US claimed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 — — US claimed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 — — US claimed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 — — US claimed
EP-2342203-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-11-04 — — EP disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 — — US disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 — — US disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 — — US disclosed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 — — US disclosed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 — — US disclosed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 — — US disclosed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 — — US disclosed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 — — US disclosed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 — — US disclosed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 — — US disclosed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 — — US disclosed
EP-2342203-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GenKyoTex SA (CH) 2011-07-13 — — EP disclosed
WO-2010035220-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2010-04-01 — — WO disclosed
WO-2010035220-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2010-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB CACNB4 1643/4885CACNA1A 1581/4885CACNA1G 2419/4885
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB CACNB4 1643/4885CACNA1A 1581/4885CACNA1G 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.